A Parallel-group Prevention, Phase II, Partially Blinded, Multi-stage Study to Investigate the Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine Formulations Compared With Licensed Meningococcal Vaccines When Administered Alone in Healthy Children (2 to 9 Years of Age) or Concomitantly With Routine Pediatric Vaccines in Toddlers (12 to 15 Months of Age) and Infants (2 Months of Age).

This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3).
Study details include:
The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.

Start Date05 Nov 2024

Sponsor / Collaborator

Sanofi Pasteur

TCTR20230923001

/ Not yet recruitingPhase 4

Immunogenicity and Safety of Pneumococcal 13-valent Conjugate Vaccine between Weuphoria and Prevnar 13 in Thai Older People

Start Date01 Nov 2024

Sponsor / Collaborator-

NCT06202703

/ RecruitingNot ApplicableIIT

Optimisation of Lymph Node Fine Needle Aspiration to Study Pneumococcal Vaccine-induced Immunity

Rationale Causing a wide range of infectious diseases, including pneumonia, otitis media and meningitis, S. pneumoniae represents an important global health problem. Pneumococcal vaccines are clinically effective in preventing invasive pneumococcal disease, but the underlying immune response is likely to differ due to the inclusion of T cell epitopes in the conjugate, but not purified polysaccharide vaccine. However, these differences remain scantly studied. Lymph node fine needle aspiration (FNA) has been recently described to study vaccine-induced germinal centre responses in depth and represents a promising tool to study the underlying immune mechanisms of pneumococcal vaccines. Insight into the underlying immune mechanisms of vaccines could improve future vaccine design, e.g. by refining dosing intervals.
Objective Determine timing of peak germinal centre B cell frequency following pneumococcal vaccination.
Main trial endpoints The main trial endpoint is represented by the frequency of germinal centre B cells (BGC) in lymph node aspirates at various time points after vaccination, as measured by spectral flow cytometry. Both total BGC cells and S. pneumoniae polysaccharide-specific BGC frequencies will be determined.
Trial design Pilot intervention study without a comparator.
Trial population Healthy individuals between the age of 20 - 40
Interventions Subjects will be vaccinated once with Prevenar13. FNA of the draining lymph node will be performed and blood will be drawn at baseline, followed by weekly collection during the first four weeks, every other week between weeks 4 - 8 and a final collection time point after 12 weeks, resulting in a total of 8 sampling time points over the course of three months. Draining lymph node size will be assessed by ultrasound every other day during the first two weeks and then alongside lymph node FNA for the remainder of the study.

Start Date15 Apr 2023

Sponsor / Collaborator-

100 Clinical Results associated with Pneumococcal polysaccharide conjugate vaccine

100 Translational Medicine associated with Pneumococcal polysaccharide conjugate vaccine

100 Patents (Medical) associated with Pneumococcal polysaccharide conjugate vaccine

516

Literatures (Medical) associated with Pneumococcal polysaccharide conjugate vaccine

01 Mar 2025·PEDIATRIC NEPHROLOGY

Poststreptococcal acute glomerulonephritis with 22F pneumococcal bacteremia

Article

Author: Yagi, Naomi ; Iwaku, Takashi ; Ikeda, Hirokazu ; Itagaki, Hinako ; Watanabe, Yoshitaka ; Kawai, Nobuhiro

BACKGROUND:

Pneumococcal vaccines have been available worldwide since the early 2000s; consequently, few reports exist of poststreptococcal acute glomerulonephritis (PSAGN) or complications of pneumococcal infection. We describe a patient with PSAGN and bacteremia with Streptococcus pneumoniae serotype 22F (not covered by the 13-valent pneumococcal vaccine (PCV 13)).

CASE DIAGNOSIS/TREATMENT:

A 5-year-old boy received the PCV13 vaccine and was admitted to our hospital with a fever and gross hematuria. A throat swab was positive for a streptococcal antigen, and his serum anti-streptolysin O and creatinine levels were increased. Low serum C3 levels suggested PSAGN, with an infiltrating shadow on chest X-ray. His blood culture isolated S. pneumoniae serotype 22F, and he was administered intravenous ceftriaxone for 10 days. His kidney function, pneumonia, and bacteremia improved.

CONCLUSIONS:

Children with PSAGN should be evaluated for pneumococcal bacteremia due to strains not covered by the vaccine.

01 Mar 2025·CLINICAL MICROBIOLOGY AND INFECTION

Comparative effectiveness of pneumococcal vaccination strategies to prevent invasive pneumococcal disease: a population-based cohort study at the veterans health administration in the United States

Article

Author: Perencevich, Eli N. ; Perencevich, Eli N ; Hasegawa, Shinya ; Goto, Michihiko ; Jones, Michael P. ; Kakiuchi, Satoshi ; Jones, Michael P

OBJECTIVES:

Comparative effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent polysaccharide vaccine (PPSV23), and their combinations for adults in preventing invasive pneumococcal disease (IPD) has yet to be thoroughly investigated. We aimed to estimate the comparative effectiveness of preventing IPD, using population-based data from the Veterans Health Administration (VHA) in the United States.

METHODS:

We included all patients who were between 65 and 74 years, had established primary care within VHA between 2005 and 2021, and had not received any prior pneumococcal vaccination. We measured time-to-event from cohort enrolment to the onset of IPD, considering death a competing risk event, and used Cox regression models to estimate cause-specific hazards. PCV13 only, PPSV23 only, PCV13 after PPSV23, and PPSV23 after PCV13 were incorporated into models as time-dependent covariates. Patient demographics and comorbidities were also included in the model.

RESULTS:

A total of 3 044 067 patients were enrolled in the cohort, with 863 958 deaths (28.4%) and 1731 cases of IPD (0.06%) during the study period. The overall incidence rate of IPD in this population was 5.36 per 100 000 patient-years. A total of 921 070 patients (30.3%) received at least one dose of effective pneumococcal vaccine. In multivariate analysis adjusted for comorbidities, PCV13 alone was not associated with the reduced risk of IPD, whereas PPSV23 had protective association with IPD incidence (adjusted hazard ratio [aHR], 0.70; 95% CI, 0.59-0.83). When combined, PCV13 followed by PPSV23 had a stronger protective association (aHR, 0.54; [0.36-0.83]) compared with PPSV23 followed by PCV13 (aHR, 0.73; [0.58-0.91]).

DISCUSSION:

In this large cohort study at the VHA, the combination of PCV13 and PPSV23, particularly PCV13 followed by PPSV23, was associated with a lower risk of IPD, indicating additional benefits in combined vaccinations with potential importance in vaccination order. Further studies are needed to evaluate the effect of newer pneumococcal vaccines.

21 Jan 2025·CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Pneumococcal serotype-specific antibodies in children with recurrent oto-sinopulmonary infections

Article

Author: Gruber, Joshua ; Blouin, William R ; Ale, Hanadys ; Taylor, Thomas ; Calderon, Jose G ; Hernández-Trujillo, Vivian P

Abstract:

Low titers to pneumococcal vaccine are a frequent finding in pediatric patients with recurrent oto-sinopulmonary infections. To characterize the pre- and post-immunization antibody trend for each serotype included in the pneumococcal 13-valent conjugate vaccine, in a cohort of pediatric patients with recurrent oto-sinopulmonary infections, this retrospective review identified 182 patients with recurrent oto-sinopulmonary infections (131 required an immune workup and 99 had low pneumococcal titers leading to a pneumococcal 13-valent conjugate vaccine booster). Baseline pneumococcal serotype-specific antibody titers at the initial visit and 6 weeks after the vaccine booster were obtained. An adequate response to the pneumococcal conjugate vaccine was deemed to be a 4-fold increase over baseline and/or a post-immunization titer of 1.3 µg/ml or greater. Overall, The pneumococcal 13-valent conjugate vaccine booster provided a significant improvement in the number of protective titers, increasing from 3.6 serotypes at baseline to 11.1 serotypes at 6 weeks (P < 0.001). This increase correlated with improved clinical outcomes (81% showed no signs of recurrent infection after the first booster and 94% after a second booster). Post-immunization antibody concentrations were significantly higher than at baseline for all serotypes (P < 0.05), and only 8, 9N, and 12F did not exhibit a greater than 4-fold increase (P > 0.05) 6 weeks following booster. There were no differences between patients at different ages in post-immunization titer levels for all serotypes. In pediatric patients with recurrent oto-sinopulmonary infections, an additional pneumococcal booster proved to be effective in the protection of these children against further infections, across all age groups.

News (Medical) associated with Pneumococcal polysaccharide conjugate vaccine

27 Jan 2025

·www.prnewswire.com

Dynavax Advances Board Refreshment Program

Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting Intends to Seek Stockholder Approval for Declassification of Board at 2025 Annual Meeting EMERYVILLE, Calif., Jan. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) (the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the following changes to its Board of Directors as part of its ongoing refreshment program: Emilio Emini, Ph.D. and Lauren Silvernail have been appointed to the Board, effective February 3, 2025. Dr. Emini will serve as a Class III director with an initial term expiring at the Company's 2027 Annual Meeting and Ms. Silvernail will serve as a Class I director with an initial term expiring at the Company's 2025 Annual Meeting. Peggy Phillips, who has served on the Dynavax Board since 2006, will retire from the Board at the 2025 Annual Meeting. Julie Eastland will step down from the Board at the 2025 Annual Meeting given her recent appointment as chief executive officer of another public company. The Board expects to appoint Ms. Silvernail as Chair of the Audit Committee and Scott Myers as Chair of the Compensation Committee following the 2025 Annual Meeting. The Board intends to seek stockholder approval at the 2025 Annual Meeting for the declassification of the Board. If stockholders approve the proposal, directors standing for election at the Company's 2026 Annual Meeting and thereafter will stand for one-year terms. Beginning with the Company's 2028 Annual Meeting, all directors will stand for election annually. Following the 2025 Annual Meeting, the Board will be comprised of nine directors, with six of its eight independent directors having been appointed since 2020. "Emilio and Lauren are two renowned leaders in their respective fields and we expect that their tremendous expertise will be immediately additive as the Company continues to execute its strategic plan and deliver for our stakeholders. Emilio has been at the forefront of some of the most notable vaccines and brings a unique perspective at the intersection of R&D, academia and public health and Lauren brings a track record of financial and operational prowess and board leadership experience within the biopharma space," said Scott Myers, Chairman of the Dynavax Board of Directors. "On behalf of the Board, I want to extend my gratitude to Peggy and Julie who have made innumerable contributions to Dynavax's growth and success over the years. Our ongoing efforts to refresh our Board with fresh perspective and expertise and enhance our governance profile are key pillars of our commitment to support Dynavax's long-term growth objectives and the changes announced today underscore this commitment." Dr. Emini said, "Dynavax has an important mission, one that I firmly share, and I am excited to work alongside the Board and the Dynavax team, a group of world-class innovators and scientists serving patients globally." Ms. Silvernail said, "Dynavax is a clear category leader with its lead asset, HEPLISAV-B, and I am eager to work with the Board to help advance the Company's strategic and financial initiatives to capitalize on its positive momentum." "We have started 2025 with strong momentum, achieving record annual revenue for HEPLISAV-B in 2024 and advancing our pipeline programs, while returning capital to our stockholders with our active $200 million share repurchase program. Through the execution of our strategic growth pillars with discipline and rigor, we will continue to focus on delivering value for our stockholders and other stakeholders, and I am looking forward to working alongside Emilio and Lauren as we look to capture the significant opportunities ahead," said Ryan Spencer, Chief Executive Officer of Dynavax. About Emilio Emini Dr. Emini brings over 40 years of experience as an executive and academic across the biopharmaceutical industry and global public health roles, helping to develop and deliver multiple anti-infectious disease interventions. Prior to his retirement, Dr. Emini served as Chief Executive Officer of the Bill & Melinda Gates Medical Research Institute and as the Director of the Foundation's Tuberculosis and HIV Programs. At the Merck Research Laboratories, from 1983 to 2004, Dr. Emini led the biological research that developed the first highly active antiretroviral therapies for HIV and led multiple vaccine research teams that contributed to many successful developments, including the vaccines for human papillomavirus and rotavirus. Following a two-year leave from the industry at the International AIDS Vaccine Initiative, Dr. Emini joined Wyeth/Pfizer as the Senior Vice President of Vaccine R&D where he led the development of the Prevenar 13® vaccine for prevention of pneumococcal disease. Dr. Emini holds a Bachelor of Science from Manhattan College and a Ph.D. in Microbiology from the Cornell University Graduate School of Medicine. About Lauren Silvernail Ms. Silvernail has three decades of experience leading finance and business development functions across the pharmaceutical industry. She most recently served as Chief Financial Officer and Executive Vice President of Corporate Development of Evolus, Inc., from 2018 until her retirement in 2022, where she led fundraising, financial and partnership activities including establishing the infrastructure for the U.S. commercial launch of the company's first approved product. Previously, she served as Chief Financial Officer and Chief Business Officer at Revance Therapeutics, Inc., where she led the company's initial public offering and subsequent rounds of financing. Prior to that, Ms. Silvernail was Chief Financial Officer and Executive Vice President of Corporate Development at ISTA Pharmaceuticals until its sale to Bausch & Lomb. Prior to that, she held corporate development roles at Allergan and other companies. Ms. Silvernail is currently a director and Audit Committee Chair of Harrow and previously served as a director and Audit Committee Chair at Harpoon Therapeutics until its successful sale to Merck and a director and Corporate Governance Committee chair at Nicox S.A. She earned an M.B.A. in finance and accounting from the Anderson Graduate School of Management at UCLA, and a B.A. in Biophysics from the University of California, Berkeley. About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit . Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "intend," "will," "may," "plan," "project," "potential," "seek," "should," "think," "toward," "will," "would" and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding the Company's plans to submit a declassification proposal at its 2025 Annual Meeting, expected contributions from newly appointed directors, the planned resignation of certain directors, anticipated committee appointments, expectations regarding delivering value for our stockholders, and our future growth and long-term performance. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including, the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change, risks relating to our ability to commercialize and supply HEPLISAV-B, and risks related to the implementation of our long-term growth objectives, as well as other risks detailed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the three months ended September 30, 2024 and periodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at is not incorporated by reference in our current periodic reports with the SEC. For Investors/Media: Paul Cox [email protected] 510-665-0499 Nicole Arndt [email protected] 510-665-7264 SOURCE Dynavax Technologies WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccineExecutive Change

30 Dec 2024

·www.globenewswire.com

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers December 23, 2024. Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease. Despite decades of public health vaccination programs, invasive pneumococcal disease (IPD) continues to inflict a substantial burden of disease, primarily due to Streptococcus pneumoniae serotypes that are not included in currently available conjugate vaccines. Next-generation PCVs have the potential to extend vaccine coverage of disease-causing serotypes. This expansion builds on the companies’ existing collaboration to develop and commercialize a PCV21 pediatric vaccine, for which the phase 3 clinical program commenced last week. This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers. Thomas Triomphe Executive Vice President, Vaccines, Sanofi “Given the vast unmet public health needs in IPD, we’re delighted to expand this collaboration and continue our pursuit of innovative work in PCV. Our collaboration leverages SK bioscience’s capabilities and Sanofi’s expertise in developing and bringing innovative vaccines to people worldwide with the collective aim of reducing the global impact of pneumococcal disease.” Jaeyong Ahn CEO and President of SK bioscience “We’re thrilled about the expansion of our collaboration with Sanofi, which serves as the core of our strategy to develop new solutions to combat pneumococcal disease. The ongoing expansion of our state-of-the-art manufacturing base, cofinanced by Sanofi, will support launch of PCV21 and future next generation vaccines.” The PCV21 phase 3 program is based on positive phase 2 results communicated last year and will include more than 7,700 infants, toddlers, young children and adolescents across multiple geographies, including the US, Europe, Australia, Asia, and Latin America. Under the terms of their expanded agreement, both companies will co-fund research and development costs. Sanofi will pay EUR 50M upfront to SK bioscience, followed by development and commercial milestone payments. Once registered, Sanofi will commercialize the vaccines worldwide except for South Korea, where SK bioscience will have commercial exclusivity. SK bioscience will receive royalty payments on product sales outside South Korea. We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. The content above comes from the network. if any infringement, please contact us to modify.

VaccineLicense out/in

03 Dec 2024

·www.echemi.com

Over 2,000 Layoffs in 19 Global Pharma Companies, Johnson & Johnson and Merck Restructure Operations in China

According to the latest monitoring data, at least 19 pharmaceutical companies globally announced layoffs or business streamlining plans in November. The impact on multinational pharmaceutical companies operating in China has been particularly significant, with Johnson & Johnson and Merck implementing layoffs in the country. Johnson & Johnson's layoffs in China reached 2,000 people, approximately 20% of its total workforce, mainly affecting the surgical division. The layoffs were primarily due to declining company performance, especially in its ultrasound knife business, which saw its market share plunge from 95% to less than 30%. Since the second quarter of this year, Johnson & Johnson has also undergone business adjustments, with several senior executives, including the president of China, Song Weiqun, leaving the company. Merck also conducted staff reductions in its China division, although the exact number of layoffs has not been specified, primarily affecting the diabetes department. Due to the impact of centralized procurement policies, Merck's diabetes drug business has suffered significantly, forcing the company to take measures to drastically reduce costs. In recent years, centralized procurement policies have driven down drug prices, leading to significant profit reductions for pharmaceutical companies, which have had to scale back or sell their operations in China in response. For example, Pfizer sold its PCV13 vaccine business and conducted extensive layoffs. In this context, other pharmaceutical companies have also announced restructuring plans. Sana Biotechnology is shifting its research focus from cancer to autoimmune diseases and has undergone strategic restructuring, though it has not disclosed the number of layoffs. Viracta Therapeutics, focusing on precision oncology, announced approximately 42% layoffs to concentrate resources on its Nana-val development project. Aurinia laid off 45% of its workforce due to an inability to find a buyer, aiming to maintain cash flow. A gene sequencing company announced a 40% reduction in staff and the termination of all therapeutic projects due to declining business and cash flow issues. Marinus Pharmaceuticals announced a 45% reduction in staff following the failure of its core drug in Phase III clinical trials. Adaptimmune stated it would lay off 33% of its workforce in Q1 2025, aiming to save $300 million over the next four years and achieve break-even by 2027. Additionally, companies such as Gilead, Sensei Biotherapeutics, Sonata, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Alector, Medigene, Novartis, and Kronos Bio have also announced layoffs or restructuring plans to respond to the current challenges in the pharmaceutical industry. These measures reflect the strategies adopted by the pharmaceutical industry in the face of market changes and policy adjustments.

VaccinePhase 3Financial Statement

100 Deals associated with Pneumococcal polysaccharide conjugate vaccine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Pneumococcal polysaccharide conjugate vaccine	J07AL02	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pneumonia, Bacterial	Japan	Pfizer Inc.	18 Jun 2013
Otitis Media	United States	Wyeth Pharmaceuticals LLC	24 Feb 2010
Acute otitis media	European Union	Pfizer Europe MA EEIG	09 Dec 2009
Acute otitis media	Iceland	Pfizer Europe MA EEIG	09 Dec 2009
Acute otitis media	Liechtenstein	Pfizer Europe MA EEIG	09 Dec 2009
Acute otitis media	Norway	Pfizer Europe MA EEIG	09 Dec 2009
Invasive streptococcal disease	European Union	Pfizer Europe MA EEIG	09 Dec 2009
Invasive streptococcal disease	Iceland	Pfizer Europe MA EEIG	09 Dec 2009
Invasive streptococcal disease	Liechtenstein	Pfizer Europe MA EEIG	09 Dec 2009
Invasive streptococcal disease	Norway	Pfizer Europe MA EEIG	09 Dec 2009
Pneumonia, Pneumococcal	European Union	Pfizer Europe MA EEIG	09 Dec 2009
Pneumonia, Pneumococcal	Iceland	Pfizer Europe MA EEIG	09 Dec 2009
Pneumonia, Pneumococcal	Liechtenstein	Pfizer Europe MA EEIG	09 Dec 2009
Pneumonia, Pneumococcal	Norway	Pfizer Europe MA EEIG	09 Dec 2009
Pneumococcal Infections	Japan	Wyeth KK	16 Oct 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacteremia	Phase 3	China	John Wyeth & Brother Ltd.	23 Jun 2018
Bacteremia	Phase 3	China	Pfizer Ltd.	23 Jun 2018
Bacteremia	Phase 3	China	Wyeth Pharmaceuticals LLC	23 Jun 2018
Bacteremia	Phase 3	China	Pfizer Investment Co. Ltd.	23 Jun 2018
Meningitis	Phase 3	China	Wyeth Pharmaceuticals LLC	23 Jun 2018
Meningitis	Phase 3	China	John Wyeth & Brother Ltd.	23 Jun 2018
Meningitis	Phase 3	China	Pfizer Investment Co. Ltd.	23 Jun 2018
Meningitis	Phase 3	China	Pfizer Ltd.	23 Jun 2018
Herpes Zoster	Phase 3	United States	GSK Plc	12 Apr 2018
Herpes Zoster	Phase 3	Canada	GSK Plc	12 Apr 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04080531 (CTgov)	Phase 4	Plasma Cell Neoplasms \| Multiple Myeloma \| Influenza, Human	165	Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Arm I (Trivalent Influenza Vaccine, Prevnar))	yovnizmdhb = kirxqdemap dsatldangj (cgpwmiiumt, crquddhbyj - xbdcasfmqr) View more	-	28 Feb 2025
				Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Trivalent Influenza Vaccine, Prevnar))	yovnizmdhb = kkttdbvuuv dsatldangj (cgpwmiiumt, qkeahwevro - agoxubambn) View more
NCT04535037 (CTgov)	Phase 4	Diphtheria	500	DTPa-HBV-IPV/Hib+Pneumococcal 13-valent conjugate vaccine (Infanrix Hexa)	acatczkdug(szozqlkdri) = uguwqpuakm hehylmvedz (ajmabreudx, noehwufvdl - gohlgmpaxg) View more	-	27 Mar 2024
				Pneumococcal 13-valent conjugate vaccine+DTaP5-HBV-IPV-Hib (Vaxelis)	acatczkdug(szozqlkdri) = eibfdvpwvu hehylmvedz (ajmabreudx, piuyfrafxv - xhqrerxnhk) View more
NCT05372575 (CTgov)	Not Applicable	Pneumonia	300	13-valent pneumococcal conjugate vaccine (13vPnC)+13vPnC (13vPnC Cohort)	prmcnehrue(gncqwvnqsg) = hgnfggkmdi wlmthccavp (ljrsryvkzb, ogxonzgqzm - ampzwkpoti) View more	-	03 Oct 2023
				13vPnC (Non-13vPnC Cohort)	prmcnehrue(gncqwvnqsg) = tzckdcpvld wlmthccavp (ljrsryvkzb, ksdliprgyk - abkrpekwgw) View more
NCT02274415 (DREVAC, Pubmed)	Phase 2	Anemia, Sickle Cell	128	13-valent pneumococcal vaccinePPSV23eumococcal vaccine (PCV13/PPSV23)	awzdzimrne(zklqlcdvxg) = oseguewkmb ltbqqdczfj (dskcdabkdb ) View more	Positive	27 Jan 2023
				PPSV2313-valent pneumococcal vaccine (PPSV23 alone)	awzdzimrne(zklqlcdvxg) = hlmnuvaevw ltbqqdczfj (dskcdabkdb ) View more
NCT03439657 (Pubmed \| J Infect)	Phase 3	-	913	Adjuvanted Recombinant Zoster Vaccine	eosqkclnuf(inrrqgnpcg): P-Value = 1.02 View more	Positive	25 Dec 2021
				13-valent Pneumococcal Conjugate Vaccine
NCT03550313 (CTgov)	Phase 2	Pneumococcal Infections	565	c7vPnC+Prevnar 13 (Group 1: c7vPnC and Prevnar 13 Co-administration)	emtwzliobt = eazvriuxel kooyekmkzq (hjhiluzdtk, zqmazpmcjc - rxzfbzpuug) View more	-	30 Nov 2021
				c7vPnC (Group 2: c7vPnC and Prevnar 13 Staggered Administration)	emtwzliobt = qxpaifwsrx kooyekmkzq (hjhiluzdtk, utongjevqo - pglchnshfk) View more
NCT03439657 (CTgov)	Phase 3	Herpes Zoster	913	HZ/su vaccine GSK1437173A+Prevenar13 (Co-Ad Group)	yiarumccml = pwvsfkrdgu egnuwpopoq (brgwfazalo, pvvfebmhcu - xlaxzibpxt) View more	-	18 Mar 2021
				HZ/su vaccine GSK1437173A+Prevenar13 (Control Group)	qnjolnqnrw(zzshqctrxd) = nrxyvgeiix gudwzobkyv (yqkbylpfdq, rzifnvfpoa - ouxyibylpo) View more
NCT02309515 (CTgov)	Phase 2	Mannose-Binding Protein Deficiency \| Lymphocytosis \| Chronic Lymphocytic Leukemia ... View more	12	Laboratory Biomarker Analysis+Lenalidomide+Pneumococcal 13-valent Conjugate Vaccine (Arm I (Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine))	yyvoqntouw = fzyzkgsajq rnjwsdbvjp (plhrnxtsch, nhezzwkveq - hyevnhatpn) View more	-	19 Jan 2021
				Laboratory Biomarker Analysis+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Pneumococcal 13-valent Conjugate Vaccine))	yyvoqntouw = uoxczozvph rnjwsdbvjp (plhrnxtsch, guqhjsqtmx - gondxqrtya) View more
NCT03548337 (CTgov)	Phase 4	-	301	MDV+rotavirus vaccine+13vPnC (13vPnC: Multi-dose Vial (With Preservative))	lyhxspfsav = iklpotfezi olgdzxnwgw (deawgjwery, mekgvhyzhe - vznhfxqdqd) View more	-	30 Sep 2020
				DTP-Hib-HBV vaccine+rotavirus vaccine+13vPnC (13vPnC: Single-dose Prefilled Syringe (Without Preservative))	lyhxspfsav = xflyyqsuez olgdzxnwgw (deawgjwery, eejhplaqyc - plvpligmsm) View more
NCT03313050 (CTgov)	Phase 2	Pneumococcal Infections	511	c7vPnC (Stage 1: c7vPnC (50 to 64 Years of Age))	ngvjpproei = etbikdaboa sahkbhotwz (obcekskvla, wxibonattd - pyathgaarc) View more	-	04 Jun 2020
				tetanus, diphtheria, and acellular pertussis vaccine (Tdap) (Stage 1: Tdap (50 to 64 Years of Age))	ngvjpproei = inihoheyvr sahkbhotwz (obcekskvla, sxxlnvghkl - rmfvahklml) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Pneumococcal polysaccharide conjugate vaccine

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation